PTPN22 R620W

PTPN22 R620W — The Master Autoimmune Switch

The PTPN22 gene encodes lymphoid tyrosine phosphatase (LYP), a critical brake on T-cell and B-cell activation. This enzyme acts as a master regulator
of immune signaling, dephosphorylating key proteins | PTPN22 dephosphorylates LCK and ZAP70, critical kinases in the T-cell receptor signaling
cascade in the T-cell receptor pathway to prevent overactivation. The R620W variant (also designated
C1858T) changes arginine to tryptophan at position 620, disrupting the protein's interaction | The R620W substitution disrupts binding between
PTPN22 and CSK kinase in the P1 proline-rich motif with its partner kinase CSK. This single amino acid
change has emerged as the strongest non-HLA genetic risk factor | PTPN22 is the most influential non-major histocompatibility complex gene to
promote autoimmunity for autoimmune disease.

The Mechanism

PTPN22 normally functions as a negative regulator of T-cell receptor signaling. The protein contains a catalytic phosphatase domain at the N-terminus
and four proline-rich motifs (P1-P4) at the C-terminus. The R620W variant sits within the P1 motif, which mediates binding to CSK. Biochemical
studies demonstrate | R620W is a gain-of-function variant showing increased phosphatase activity and reduced Lck phosphorylation feedback
regulation that the variant exhibits enhanced phosphatase activity while losing normal regulatory
feedback. The disrupted PTPN22-CSK interaction impairs phosphorylation of PTPN22 at Y536, removing an inhibitory mechanism | Y536 phosphorylation
normally inhibits PTPN22 activity; R620W reduces this phosphorylation, creating sustained inhibition
that normally dampens the phosphatase. The net effect is a gain-of-function variant that excessively inhibits T-cell signaling | The R620W variant
creates gain-of-function inhibition of TCR signaling particularly affecting low-avidity T cell
responses—but paradoxically increases autoimmune risk.

The mechanism explains this apparent paradox: PTPN22 R620W preferentially affects responses to low-avidity antigens | Loss of PTPN22 function
selectively impacts T-cell responses to weak self-antigens but not high-avidity antigens—precisely the
type of self-antigens that should trigger tolerance. Gene editing studies in human T cells | CRISPR-engineered R620W variant in human cord blood
T cells showed enhanced proliferation and Th1 skewing with low-avidity self-reactive TCRs confirm that
the variant permits increased activation of weakly self-reactive T cells, potentially expanding the self-reactive T-cell pool and skewing toward
inflammatory phenotypes. This allows mildly autoreactive T cells to escape negative selection, setting the stage for autoimmune attack.

The Evidence

PTPN22 R620W was first associated with type 1 diabetes in 2004 | Initial discovery linked R620W to type 1 diabetes with consistent replication
across multiple populations, rapidly followed by associations with rheumatoid arthritis and systemic
lupus erythematosus. A meta-analysis of rheumatoid arthritis | Study of 1,413 cases found OR=1.75 for RF-positive RA; homozygotes showed OR=4.57,
more than doubling disease risk found odds ratios of 1.75 for heterozygotes and 4.57 for homozygotes—a
clear dose-dependent effect. The variant shows an additive inheritance pattern | Meta-analysis supported additive rather than dominant effect on
type 1 diabetes risk, with each copy incrementally increasing risk.

The variant displays marked population stratification | 1858T allele frequency is ~7% in Europeans, ~1% in Asians, extremely rare in
Africans: approximately 7% allele frequency in European populations, 1-2% in Asian populations, and
near-absent in African populations. This distribution explains why autoimmune disease associations were first identified in European cohorts.
Diseases with documented R620W associations | PTPN22 R620W associated with RA, T1D, SLE, Graves' disease, vitiligo, alopecia areata, celiac
disease, and myasthenia gravis include rheumatoid arthritis, type 1 diabetes, systemic lupus
erythematosus, Graves' disease, vitiligo, alopecia areata, celiac disease, and myasthenia gravis. Notably, the variant shows no association | No
association detected with multiple sclerosis or inflammatory bowel disease with multiple sclerosis or
inflammatory bowel disease, suggesting specificity for antibody-mediated autoimmune conditions.

Recent cross-trait meta-analyses | rs2476601-A identified as shared risk locus between vitiligo and alopecia areata in GWAS
meta-analysis identified rs2476601 as a shared risk locus between vitiligo and alopecia areata,
autoimmune skin conditions affecting melanocytes and hair follicles. A meta-analysis specific to alopecia | Systematic review found T allele
significantly correlated with AA susceptibility; C allele protective found the T (risk) allele
significantly correlated with alopecia areata susceptibility while the C allele was protective.

Practical Implications

If you carry one or two copies of the risk allele (AG or AA genotype), you have elevated baseline risk for multiple autoimmune conditions. This
doesn't mean you'll develop these diseases—most carriers remain healthy—but awareness enables proactive monitoring and early intervention. The
risk is highest for seropositive disease | PTPN22 association strongest with RF-positive RA and antibody-positive
autoimmunity forms characterized by autoantibody production (RF-positive rheumatoid arthritis,
anti-thyroid antibodies in Graves' disease, anti-dsDNA in lupus).

Pay attention to early warning signs of autoimmune disease: unexplained joint pain or swelling, chronic fatigue, skin changes including vitiligo
patches or patchy hair loss, thyroid dysfunction symptoms, or recurrent inflammatory episodes. If you develop one autoimmune condition, your risk
for additional autoimmune diseases is elevated—PTPN22 R620W predisposes to clustering of autoimmune conditions | Risk from 1858T allele increased
in patients with family history of other autoimmune diseases within individuals and families.

For women planning pregnancy, note that autoimmune diseases often flare postpartum due to immune system rebound. Pregnancy with known PTPN22 risk
alleles warrants closer monitoring by rheumatology or immunology specialists. If you have family history of autoimmune disease combined with R620W
carrier status, consider baseline autoantibody screening (ANA panel, RF, anti-TPO, anti-CCP depending on symptoms) to catch subclinical
autoimmunity.

Interactions

PTPN22 R620W interacts with HLA haplotypes—the strongest autoimmune risk factors—in a synergistic rather than additive manner. Studies show no
genetic epistasis | No evidence of genetic association between PTPN22 and HLA susceptibility alleles in rheumatoid
arthritis between PTPN22 and HLA-DR shared epitope alleles in rheumatoid arthritis, suggesting
independent but convergent mechanisms. However, the combination of PTPN22 risk variant with high-risk HLA haplotypes | PTPN22 T/T and C/T
genotypes more frequent in T1D cases without high-risk HLA DR3/4-DQ8 (HLA-DR3/4-DQ8 for type 1
diabetes, HLA-DRB1 shared epitope for RA) substantially elevates absolute disease risk beyond what either confers alone.

Within the PTPN22 locus, multiple SNPs contribute to risk | Two SNPs (rs3811021, rs3789605) on separate haplotype associated with RA independent
of R620W. Haplotype analysis shows rs2476601 interacts with rs1310182 and rs3789604: the minor
allele of rs3789604 amplifies R620W risk | rs3789604 minor allele increased R620W OR to 2.53 for homozygotes and 1.77 for
heterozygotes, while rs1310182 minor allele modestly reduces it. These haplotype effects underscore
that R620W, while the primary driver, doesn't fully account for PTPN22's autoimmune associations.

In vitiligo and alopecia areata, PTPN22 R620W combines with HLA class II variants | Shared genetic architecture includes rs2476601-A plus
HLA-DRB6, HLA-DQA2, HLA-DRB1, and HLA-DQA1 variants to create compound autoimmune risk affecting skin
pigmentation and hair follicles.